Ecnoglutide Guide
XANO Pharmaceuticals
Complete guide to Ecnoglutide. Ecnoglutide (XW003) is a long-acting GLP-1 receptor agonist developed by Sciwind Biosciences / XANO Pharmaceuticals. In ..
XANO Pharmaceuticals\' GLP-1 Receptor Agonist
Ecnoglutide (XW003) is a long-acting GLP-1 receptor agonist developed by Sciwind Biosciences / XANO Pharmaceuticals. In Phase 2 trials, it demonstrated up to approximately 16% weight loss over 24 weeks in adults with obesity. Its development adds to the growing global pipeline of GLP-1 therapies aiming to provide more accessible treatment options. Use the Shotlee app to track your current protocol and build baseline data for whatever comes next.
What Is Ecnoglutide?
Ecnoglutide (XW003) is a long-acting GLP-1 receptor agonist developed by Sciwind Biosciences / XANO Pharmaceuticals. In Phase 2 trials, it demonstrated up to approximately 16% weight loss over 24 weeks in adults with obesity. Its development adds to the growing global pipeline of GLP-1 therapies aiming to provide more accessible treatment options.
Track your current protocol in Shotlee while this science evolves. Having clean historical data means you can compare outcomes with precision if you ever switch medications.
How It Works
GLP-1 Targeting
Potent GLP-1 receptor activation. Sustained appetite suppression. Once-weekly injection. Track doses in Shotlee
Metabolic Effects
Improved glucose control. Insulin sensitivity benefits. Cardiometabolic improvements. Log labs in Shotlee
Clinical Promise
Competitive weight loss results. 16% in 24 weeks (Phase 2). Global development pipeline. Monitor progress in Shotlee
Why This Matters
Ecnoglutide\'s Phase 2 results showing 16% weight loss in just 24 weeks are competitive with established GLP-1s. More options in the GLP-1 class mean more choices for patients and potentially better p
Clinical Data
Top dose (24 wks)
~16%
Safety
Manageable
Side Effects
Nausea (dose-dependent)
GI discomfort
Decreased appetite
Track symptoms in Shotlee
Vital Protocol FAQs
What is Ecnoglutide?
Ecnoglutide (XW003) is a long-acting GLP-1 receptor agonist showing approximately 16% weight loss in 24-week Phase 2 trials. Track your GLP-1 protocol in the Shotlee app.
How does it compare to Semaglutide?
Both are GLP-1 agonists. Ecnoglutide\'s 16% loss in 24 weeks is competitive, but head-to-head data is needed. Use Shotlee to compare your own results across medications.
Guide FAQs
Complete guide to Ecnoglutide. Ecnoglutide (XW003) is a long-acting GLP-1 receptor agonist developed by Sciwind Biosciences / XANO Pharmaceuticals. In ..
Yes. Shotlee supports tracking Ecnoglutide doses, side effects, and health metrics. It is free to use.
References
Track Your Ecnoglutide Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.
🚀 Use Shotlee for Free